Related Experiment Video

Updated: Oct 10, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.0K

Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease

Ji Yeon Lee1, Jee Young Lee2, Jae-Hoon Ko3

  • 1Division of Infectious Diseases, Department of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, South Korea.

Frontiers in Immunology
|December 13, 2021
PubMed

Insights

Regdanvimab, a monoclonal antibody, significantly reduced the risk of progression to severe coronavirus 2019 (COVID-19) in mild cases. This treatment also decreased the need for oxygen supplementation in hospitalized patients.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Clinical Medicine

Background:

  • Coronavirus 2019 (COVID-19) poses a significant global health challenge.
  • Identifying effective treatments for COVID-19, particularly for patients at risk of progression, is crucial.
  • Monoclonal antibodies have emerged as a therapeutic option for viral infections.

Purpose of the Study:

  • To evaluate the clinical effectiveness of regdanvimab, a monoclonal antibody, in treating patients with mild COVID-19.
  • To assess the impact of regdanvimab on disease progression and the need for respiratory support.

Main Methods:

  • A retrospective cohort study involving 778 mild COVID-19 patients was conducted.
  • Patients were classified into regdanvimab and supportive care groups.
  • Multivariate analyses were performed on total and propensity score-matched cohorts to assess disease progression.

Main Results:

  • Regdanvimab treatment was associated with significantly lower rates of oxygen supplementation (8.1% vs 18.4%) and progression to severe disease (2.1% vs 9.6%) compared to supportive care.
  • Multivariate analysis confirmed a reduced risk for progression to severe disease in both total (HR 0.262) and PS-matched (HR 0.176) cohorts.
  • Low SpO2 and elevated CRP were identified as risk factors for disease progression.

Conclusions:

  • Regdanvimab treatment demonstrated clinical effectiveness in reducing the risk of progression to severe COVID-19 in mild cases.
  • The findings support the use of regdanvimab as a therapeutic option for high-risk COVID-19 patients.
  • Further research may explore optimal timing and patient selection for regdanvimab therapy.
Abstract

Keywords:
COVID-19Regdanvimabmonoclonal antibodyoutcomeprogression

More Related Videos

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

3.7K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

793

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
30
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
492
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
284
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
49
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
355
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
40